{"id":106367,"date":"2024-02-28T19:22:00","date_gmt":"2024-02-28T12:22:00","guid":{"rendered":"https:\/\/www.xinwengao.com\/cn\/pr\/20240228192200106367"},"modified":"2024-02-29T00:24:37","modified_gmt":"2024-02-28T16:24:37","slug":"%e9%a9%af%e9%b9%bf%e7%94%9f%e7%89%a9%e4%bc%8a%e5%9f%ba%e5%a5%a5%e4%bb%91%e8%b5%9b%e6%b3%a8%e5%b0%84%e6%b6%b2%e6%b2%bb%e7%96%97%e9%9a%be%e6%b2%bb%e6%80%a7%e9%87%8d%e7%97%87%e8%82%8c%e6%97%a0%e5%8a%9bm","status":"publish","type":"post","link":"https:\/\/www.xinwengao.com\/cn\/pr\/20240228192200106367","title":{"rendered":"\u9a6f\u9e7f\u751f\u7269\u4f0a\u57fa\u5965\u4ed1\u8d5b\u6ce8\u5c04\u6db2\u6cbb\u7597\u96be\u6cbb\u6027\u91cd\u75c7\u808c\u65e0\u529b(MG)\u75c5\u4f8b\u62a5\u544a\u5728\u300aEMBO Molecular Medicine\u300b\u53d1\u8868"},"content":{"rendered":"<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/www.xinwengao.com\/cn\/wp-content\/uploads\/1_Logo-4.jpg\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><p><span class=\"legendSpanClass\">\u4e2d\u56fd\u5357\u4eac\u3001\u4e0a\u6d77\u548c\u52a0\u5dde\u5723\u8377\u897f<\/span><span class=\"legendSpanClass\">2024\u5e742\u670828\u65e5<\/span> \/\u7f8e\u901a\u793e\/ &#8212; <b>2024\u5e742\u670826\u65e5\uff0c\u56fd\u9645\u6743\u5a01\u5b66\u672f\u671f\u520a\u300aEMBO Molecular Medicine\u300b\u6b63\u5f0f\u53d1\u8868\u4e86\u9a6f\u9e7f\u751f\u7269\u5168\u4eba\u6e90\u9776\u5411BCMA\u5d4c\u5408\u6297\u539f\u53d7\u4f53\u81ea\u4f53T\uff08BCMA CAR-T\uff09\u7ec6\u80de\u6ce8\u5c04\u6db2\uff08\u4f0a\u57fa\u5965\u4ed1\u8d5b\u6ce8\u5c04\u6db2\uff0c\u7814\u53d1\u4ee3\u53f7CT103A\uff09\u6cbb\u75972\u4f8b\u96be\u6cbb\u6027\u91cd\u75c7\u808c\u65e0\u529b\uff08Myasthenia gravis, MG\uff09\u53d7\u8bd5\u8005\u7684\u4e34\u5e8a\u7814\u7a76\u8bba\u6587\u2014\u2014B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis<\/b>, \u521d\u6b65\u5c55\u73b0\u4e86BCMA CAR-T\u7597\u6cd5\u5728MG\u6cbb\u7597\u4e2d\u7684\u826f\u597d\u8010\u53d7\u6027\u548c\u5b89\u5168\u6027\u4ee5\u53ca\u6301\u4e45\u7684\u4e34\u5e8a\u7597\u6548\u3002<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<\/p><\/div>\n<p>MG\u662f\u7531\u81ea\u8eab\u6297\u4f53\u4ecb\u5bfc\u7684\u83b7\u5f97\u6027\u795e\u7ecf-\u808c\u8089\u63a5\u5934\uff08neuromuscular junction,NMJ\uff09\u4f20\u9012\u969c\u788d\u7684\u81ea\u8eab\u514d\u75ab\u6027\u75be\u75c5\u3002\u4e59\u9170\u80c6\u78b1\u53d7\u4f53\uff08acetylcholine receptor,AChR\uff09\u6297\u4f53\u662f\u6700\u5e38\u89c1\u7684\u81f4\u75c5\u6027\u6297\u4f53\uff1b\u6b64\u5916\uff0c\u9488\u5bf9\u7a81\u89e6\u540e\u819c\u5176\u4ed6\u7ec4\u5206\uff0c\u5305\u62ec\u808c\u8089\u7279\u5f02\u6027\u53d7\u4f53\u916a\u6c28\u9178\u6fc0\u9176\uff08muscle-specific receptor tyrosine kinase,MuSK\uff09\u3001\u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d\u53d7\u4f53\u76f8\u5173\u86cb\u767d4\uff08low-density lipoprotein receptor-related protein 4,LRP4\uff09\u53ca\u5170\u5c3c\u78b1\u53d7\u4f53\uff08ryanodine receptor,RyR\uff09\u7b49\u6297\u4f53\u9646\u7eed\u88ab\u53d1\u73b0\u53c2\u4e0eMG\u53d1\u75c5\u3002\u76ee\u524d\uff0cMG\u7684\u6cbb\u7597\u4ecd\u4ee5\u80c6\u78b1\u916f\u9176\u6291\u5236\u5242\u3001\u7cd6\u76ae\u8d28\u6fc0\u7d20\u3001\u514d\u75ab\u6291\u5236\u5242\u3001\u9759\u8109\u6ce8\u5c04\u514d\u75ab\u7403\u86cb\u767d\u3001\u8840\u6d46\u7f6e\u6362\u4ee5\u53ca\u80f8\u817a\u5207\u9664\u4e3a\u4e3b\u3002\u60a3\u8005\u4e3b\u8981\u7684\u6b7b\u4ea1\u539f\u56e0\u5305\u62ec\u547c\u5438\u8870\u7aed\u3001\u80ba\u90e8\u611f\u67d3\u7b49\u3002<\/p>\n<p>\u8be5\u7814\u7a76\u4e3a\u4e00\u9879\u7814\u7a76\u8005\u53d1\u8d77\u7684\u5f00\u653e\u8bc4\u4ef7\u8f93\u6ce8\u4f0a\u57fa\u5965\u4ed1\u8d5b\u6ce8\u5c04\u6db2\u6cbb\u7597\u590d\u53d1\/\u96be\u6cbb\u6027\u6297\u4f53\u4ecb\u5bfc\u7684\u795e\u7ecf\u7cfb\u7edf\u7279\u53d1\u6027\u708e\u75c7\u6027\u75be\u75c5\u7684\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\u7684\u63a2\u7d22\u6027\u4e34\u5e8a\u7814\u7a76\uff08NCT04561557\uff09\uff0c\u7814\u7a76\u8005\u4e3a\u534e\u4e2d\u79d1\u6280\u5927\u5b66\u540c\u6d4e\u533b\u5b66\u9662\u9644\u5c5e\u540c\u6d4e\u533b\u9662\u738b\u4f1f\u6559\u6388\u56e2\u961f\u3002<\/p>\n<p>\u8be5\u7814\u7a76\u4e2d\u5165\u7ec4\u4e862\u4f8b\u96be\u6cbb\u6027MG\u53d7\u8bd5\u8005\uff0c\u5176\u4e2d1\u4f8b\u53d7\u8bd5\u8005\u4e3a33\u5c81\u5973\u6027\uff0cAChR-IgG\u548cTitin-IgG\u9633\u6027\uff0c\u5165\u7ec4\u524d21\u4e2a\u6708\u63a5\u53d7\u4e86\u80f8\u817a\u5207\u9664\u672f\u6cbb\u7597\uff0c\u7ecf\u80c6\u78b1\u916f\u9176\u6291\u5236\u5242\u3001\u7cd6\u76ae\u8d28\u6fc0\u7d20\u3001\u514d\u75ab\u6291\u5236\u5242\u53ca\u9776\u5411CD20\u5355\u6297\u6cbb\u7597\u4ecd\u672a\u8fbe\u5230\u4e34\u5e8a\u7f13\u89e3\uff1b\u53e61\u4f8b\u53d7\u8bd5\u8005\u4e3a60\u5c81\u5973\u6027\uff0cMuSK-IgG4\u9633\u6027\uff0c20\u5e74\u75c5\u53f2\uff0c\u65e2\u5f80\u63a5\u53d7\u8fc7\u6fc0\u7d20\u3001\u514d\u75ab\u6291\u5236\u5242\u3001\u9776\u5411CD20\u5355\u6297\u7b49\u591a\u79cd\u6cbb\u7597\u65e0\u6548\u30022\u4f8b\u53d7\u8bd5\u8005\u5206\u522b\u63a5\u53d7\u4e861.01&times;10<sup>6<\/sup>CAR-T\/Kg\u548c0.96&times;10<sup>6<\/sup>CAR-T\/Kg\u7684\u4f0a\u57fa\u5965\u4ed1\u8d5b\u6ce8\u5c04\u6db2\u5355\u6b21\u56de\u8f93\u6cbb\u7597\u3002<\/p>\n<p><b>\u5b89\u5168\u6027<\/b>\uff1a2\u4f8b\u53d7\u8bd5\u8005\u4e2d\uff0c\u4ec51\u4f8b\u53d7\u8bd5\u8005\u53d1\u751f\u4e861\u7ea7\u7684\u7ec6\u80de\u56e0\u5b50\u91ca\u653e\u7efc\u5408\u5f81\uff08Cytokine Release Syndrome\uff0cCRS\uff09\uff0c\u672a\u53d1\u751f\u514d\u75ab\u6548\u5e94\u7ec6\u80de\u76f8\u5173\u795e\u7ecf\u6bd2\u6027\u7efc\u5408\u5f81\uff08Immune effector Cell-Associated Neurotoxicity Syndrome\uff0cICANS\uff09\uff0c\u22653\u7ea7\u7684\u8840\u7ec6\u80de\u51cf\u5c11\u5747\u5728\u56de\u8f93\u540e4\u5468\u5185\u6062\u590d\u3002\u76f8\u8f83\u4e8e\u5728\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u9002\u5e94\u75c7\u7814\u7a76\u4e2d\u7684\u5b89\u5168\u6027\u8c31\uff0c\u672a\u53d1\u73b0\u65b0\u7684\u5b89\u5168\u6027\u98ce\u9669\uff0c\u4e14\u5b89\u5168\u6027\u66f4\u4f18\u3002<\/p>\n<p><b>\u6709\u6548\u6027<\/b>\uff1a2\u4f8b\u53d7\u8bd5\u8005\u7684\u4e34\u5e8a\u75c7\u72b6\u6301\u7eed\u6539\u5584\u8d85\u8fc718\u4e2a\u6708\u3002\u4f0a\u57fa\u5965\u4ed1\u8d5b\u6ce8\u5c04\u6db2\u56de\u8f93\u540e3\u4e2a\u6708\u5f00\u59cb\uff0c\u60a3\u8005\u80a2\u529b\u548c\u80ba\u6d3b\u91cf\u660e\u663e\u6539\u5584\uff0c\u91cd\u75c7\u808c\u65e0\u529b-\u65e5\u5e38\u751f\u6d3b\u6d3b\u52a8\u8bc4\u5206\uff08MG-ADL\uff09\u3001\u91cd\u75c7\u808c\u65e0\u529b\u5b9a\u91cf\u8bc4\u5206\uff08QMG\uff09\u3001\u91cd\u75c7\u808c\u65e0\u529b-\u751f\u6d3b\u8d28\u91cf\u8bc4\u5206\uff08MG-QOL\uff09\u548c\u6539\u826fRankin\u8bc4\u5206\uff08mRS\uff09\u6301\u7eed\u6539\u5584\u3002\u968f\u8bbf\u671f\u95f4\u9664\u5916\u4f4e\u5242\u91cf\u65b0\u65af\u7684\u660e\uff08\u5206\u522b\u4e3a90mg\/\u5929\u548c60mg\/\u5929\uff09\uff0c\u672a\u5408\u5e76\u4f7f\u7528\u5176\u4ed6\u514d\u75ab\u8c03\u8282\u6cbb\u7597\u3002<\/p>\n<p><b>PK\/PD<\/b>\uff1a\u4f0a\u57fa\u5965\u4ed1\u8d5b\u6ce8\u5c04\u6db2\u56de\u8f93\u540e\u5728\u53d7\u8bd5\u8005\u4f53\u5185\u6269\u589e\u826f\u597d\uff0c\u6301\u7eed\u65f6\u95f4\u8f83\u77ed\u30022\u4f8b\u53d7\u8bd5\u8005\u7684\u6297AChR\u548c\u6297Titin\u6297\u4f53\u3001\u6297MuSK\u6297\u4f53\u5728\u56de\u8f93\u540e\u5747\u8fc5\u901f\u964d\u4f4e\u5e76\u957f\u671f\u7ef4\u6301\u5728\u6781\u4f4e\u6c34\u5e73\u30022\u4f8b\u53d7\u8bd5\u8005\u7684B\u7ec6\u80de\u548c\u6d46\u7ec6\u80de\u5728\u56de\u8f93\u540e2\u4e2a\u6708\u5185\u964d\u4f4e\u81f3\u65e0\u6cd5\u68c0\u6d4b\uff0c\u800c\u540e\u9010\u6e10\u6062\u590d\u3002\u4e24\u4f8b\u53d7\u8bd5\u8005\u7684B\u7ec6\u80de\u5728\u56de\u8f93\u540e18\u4e2a\u6708\u5747\u5df2\u6062\u590d\u81f3\u6b63\u5e38\u6c34\u5e73\uff0c\u5176\u4e2d\u7ea680%\u4e3a\u5e7c\u7a1aB\u7ec6\u80de\uff0c\u800c\u6d46\u7ec6\u80de\u4ecd\u7ef4\u6301\u8f83\u4f4e\u6c34\u5e73\u3002\u8be5\u7ed3\u679c\u663e\u793aCAR-T\u7ec6\u80de\u6cbb\u7597\u7684\u957f\u671f\u7597\u6548\uff0c\u53ef\u80fd\u4e0e\u5e7c\u7a1a\u8868\u578b\u4e3a\u4e3b\u7684B\u7ec6\u80de\u91cd\u5efa\u800c\u6d46\u7ec6\u80de\u6301\u7eed\u6e05\u9664\u6709\u5173\u3002<\/p>\n<p>\u6b64\u9879\u7814\u7a76\u4e3b\u8981\u7814\u7a76\u8005\uff0c<b>\u534e\u4e2d\u79d1\u6280\u5927\u5b66\u540c\u6d4e\u533b\u5b66\u9662\u9644\u5c5e\u540c\u6d4e\u533b\u9662\u738b\u4f1f\u6559\u6388\u8868\u793a<\/b>\uff1a&quot;\u91cd\u75c7\u808c\u65e0\u529b\u75c5\u7a0b\u957f\u3001\u96be\u6cbb\u6108\u3001\u6613\u590d\u53d1\uff0c\u5f53\u524d\u4f20\u7edf\u836f\u7269\u7684\u6cbb\u7597\u867d\u5728\u4e00\u5b9a\u7a0b\u5ea6\u4e0a\u80fd\u6539\u5584\u808c\u65e0\u529b\u75c7\u72b6\uff0c\u4f46\u5728\u75be\u75c5\u63a7\u5236\u3001\u957f\u671f\u5b89\u5168\u6027\u7b49\u65b9\u9762\u5747\u5b58\u5728\u4e0d\u8db3\uff0c\u60a3\u8005\u5bf9\u66f4\u597d\u7684\u4e34\u5e8a\u7ed3\u5c40\u548c\u6cbb\u7597\u65b9\u5f0f\u6709\u8feb\u5207\u9700\u6c42\u3002\u5728\u6211\u4eec\u6b64\u6b21\u7684IIT\u7814\u7a76\u4e2d\uff0c\u5f88\u9ad8\u5174\u5730\u770b\u5230BCMA CAR-T\u7ec6\u80de\u7597\u6cd5\u53ef\u4ee5\u963b\u6b62MG\u75be\u75c5\u8fdb\u5c55\uff0c\u5e76\u8868\u73b0\u51fa\u9006\u8f6c\u75be\u75c5\u5f81\u8c61\uff0c\u6709\u671b\u6539\u53d8MG\u6cbb\u7597\u683c\u5c40\uff0c\u4e3a\u60a3\u8005\u5e26\u6765\u6cbb\u6108\u7684\u5e0c\u671b\u3002&quot;<\/p>\n<p>\u9664\u672c\u6b21\u53d1\u8868\u7684\u7814\u7a76\u7ed3\u679c\u5916\uff0c\u9a6f\u9e7f\u751f\u7269\u548c\u7814\u7a76\u8005\u56e2\u961f\u4ecd\u5728\u6301\u7eed\u63a2\u7d22\u4f0a\u57fa\u5965\u4ed1\u8d5b\u6ce8\u5c04\u6db2\u5728\u6cbb\u7597\u5176\u4ed6\u6297\u4f53\u4ecb\u5bfc\u7684\u81ea\u8eab\u514d\u75ab\u6027\u75be\u75c5\u5305\u62ec\u89c6\u795e\u7ecf\u810a\u9ad3\u708e\u8c31\u7cfb\u75be\u75c5\uff08NMOSD\uff09\u3001\u514d\u75ab\u4ecb\u5bfc\u6027\u574f\u6b7b\u6027\u808c\u75c5\uff08IMNM\uff09\u4ee5\u53ca\u6162\u6027\u708e\u6027\u8131\u9ad3\u9798\u6027\u591a\u53d1\u6027\u795e\u7ecf\u75c5\uff08CIDP\uff09\u4e2d\u7684\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\uff0c\u81f4\u529b\u4e8e\u6539\u53d8\u81ea\u514d\u75be\u75c5\u7684\u6cbb\u7597\u683c\u5c40\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u4e2d\u56fd\u5357\u4eac\u3001\u4e0a\u6d77\u548c\u52a0\u5dde\u5723\u8377\u897f2024\u5e742\u670828\u65e5 \/\u7f8e\u901a\u793e\/ &#8212; 2024\u5e742\u670826\u65e5\uff0c\u56fd\u9645\u6743\u5a01\u5b66\u672f\u671f\u520a\u300aEMBO Molecular Medicine\u300b\u6b63\u5f0f\u53d1\u8868\u4e86\u9a6f\u9e7f\u751f\u7269\u5168\u4eba\u6e90\u9776\u5411BCMA\u5d4c\u5408\u6297\u539f\u53d7\u4f53\u81ea\u4f53T\uff08BCMA CAR-T\uff09\u7ec6\u80de\u6ce8\u5c04\u6db2\uff08\u4f0a\u57fa\u5965\u4ed1\u8d5b\u6ce8\u5c04\u6db2\uff0c\u7814\u53d1\u4ee3\u53f7CT103A\uff09\u6cbb\u75972\u4f8b\u96be\u6cbb\u6027\u91cd\u75c7\u808c\u65e0\u529b\uff08Myasthenia gravis, MG\uff09\u53d7\u8bd5\u8005\u7684\u4e34\u5e8a\u7814\u7a76\u8bba\u6587\u2014\u2014B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis, \u521d\u6b65\u5c55\u73b0\u4e86BCMA CAR-T\u7597\u6cd5\u5728MG\u6cbb\u7597\u4e2d\u7684\u826f\u597d\u8010\u53d7\u6027\u548c\u5b89\u5168\u6027\u4ee5\u53ca\u6301\u4e45\u7684\u4e34\u5e8a\u7597\u6548\u3002 MG\u662f\u7531\u81ea\u8eab\u6297\u4f53\u4ecb\u5bfc\u7684\u83b7\u5f97\u6027\u795e\u7ecf-\u808c\u8089\u63a5\u5934\uff08neuromuscular junction,NMJ\uff09\u4f20\u9012\u969c\u788d\u7684\u81ea\u8eab\u514d\u75ab\u6027\u75be\u75c5\u3002\u4e59\u9170\u80c6\u78b1\u53d7\u4f53\uff08acetylcholine receptor,AChR\uff09\u6297\u4f53\u662f\u6700\u5e38\u89c1\u7684\u81f4\u75c5\u6027\u6297\u4f53\uff1b\u6b64\u5916\uff0c\u9488\u5bf9\u7a81\u89e6\u540e\u819c\u5176\u4ed6\u7ec4\u5206\uff0c\u5305\u62ec\u808c\u8089\u7279\u5f02\u6027\u53d7\u4f53\u916a\u6c28\u9178\u6fc0\u9176\uff08muscle-specific receptor tyrosine kinase,MuSK\uff09\u3001\u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d\u53d7\u4f53\u76f8\u5173\u86cb\u767d4\uff08low-density lipoprotein receptor-related protein 4,LRP4\uff09\u53ca\u5170\u5c3c\u78b1\u53d7\u4f53\uff08ryanodine receptor,RyR\uff09\u7b49\u6297\u4f53\u9646\u7eed\u88ab\u53d1\u73b0\u53c2\u4e0eMG\u53d1\u75c5\u3002\u76ee\u524d\uff0cMG\u7684\u6cbb\u7597\u4ecd\u4ee5\u80c6\u78b1\u916f\u9176\u6291\u5236\u5242\u3001\u7cd6\u76ae\u8d28\u6fc0\u7d20\u3001\u514d\u75ab\u6291\u5236\u5242\u3001\u9759\u8109\u6ce8\u5c04\u514d\u75ab\u7403\u86cb\u767d\u3001\u8840\u6d46\u7f6e\u6362\u4ee5\u53ca\u80f8\u817a\u5207\u9664\u4e3a\u4e3b\u3002\u60a3\u8005\u4e3b\u8981\u7684\u6b7b\u4ea1\u539f\u56e0\u5305\u62ec\u547c\u5438\u8870\u7aed\u3001\u80ba\u90e8\u611f\u67d3\u7b49\u3002 \u8be5\u7814\u7a76\u4e3a\u4e00\u9879\u7814\u7a76\u8005\u53d1\u8d77\u7684\u5f00\u653e\u8bc4\u4ef7\u8f93\u6ce8\u4f0a\u57fa\u5965\u4ed1\u8d5b\u6ce8\u5c04\u6db2\u6cbb\u7597\u590d\u53d1\/\u96be\u6cbb\u6027\u6297\u4f53\u4ecb\u5bfc\u7684\u795e\u7ecf\u7cfb\u7edf\u7279\u53d1\u6027\u708e\u75c7\u6027\u75be\u75c5\u7684\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\u7684\u63a2\u7d22\u6027\u4e34\u5e8a\u7814\u7a76\uff08NCT04561557\uff09\uff0c\u7814\u7a76\u8005\u4e3a\u534e\u4e2d\u79d1\u6280\u5927\u5b66\u540c\u6d4e\u533b\u5b66\u9662\u9644\u5c5e\u540c\u6d4e\u533b\u9662\u738b\u4f1f\u6559\u6388\u56e2\u961f\u3002 \u8be5\u7814\u7a76\u4e2d\u5165\u7ec4\u4e862\u4f8b\u96be\u6cbb\u6027MG\u53d7\u8bd5\u8005\uff0c\u5176\u4e2d1\u4f8b\u53d7\u8bd5\u8005\u4e3a33\u5c81\u5973\u6027\uff0cAChR-IgG\u548cTitin-IgG\u9633\u6027\uff0c\u5165\u7ec4\u524d21\u4e2a\u6708\u63a5\u53d7\u4e86\u80f8\u817a\u5207\u9664\u672f\u6cbb\u7597\uff0c\u7ecf\u80c6\u78b1\u916f\u9176\u6291\u5236\u5242\u3001\u7cd6\u76ae\u8d28\u6fc0\u7d20\u3001\u514d\u75ab\u6291\u5236\u5242\u53ca\u9776\u5411CD20\u5355\u6297\u6cbb\u7597\u4ecd\u672a\u8fbe\u5230\u4e34\u5e8a\u7f13\u89e3\uff1b\u53e61\u4f8b\u53d7\u8bd5\u8005\u4e3a60\u5c81\u5973\u6027\uff0cMuSK-IgG4\u9633\u6027\uff0c20\u5e74\u75c5\u53f2\uff0c\u65e2\u5f80\u63a5\u53d7\u8fc7\u6fc0\u7d20\u3001\u514d\u75ab\u6291\u5236\u5242\u3001\u9776\u5411CD20\u5355\u6297\u7b49\u591a\u79cd\u6cbb\u7597\u65e0\u6548\u30022\u4f8b\u53d7\u8bd5\u8005\u5206\u522b\u63a5\u53d7\u4e861.01&times;106CAR-T\/Kg\u548c0.96&times;106CAR-T\/Kg\u7684\u4f0a\u57fa\u5965\u4ed1\u8d5b\u6ce8\u5c04\u6db2\u5355\u6b21\u56de\u8f93\u6cbb\u7597\u3002 \u5b89\u5168\u6027\uff1a2\u4f8b\u53d7\u8bd5\u8005\u4e2d\uff0c\u4ec51\u4f8b\u53d7\u8bd5\u8005\u53d1\u751f\u4e861\u7ea7\u7684\u7ec6\u80de\u56e0\u5b50\u91ca\u653e\u7efc\u5408\u5f81\uff08Cytokine Release Syndrome\uff0cCRS\uff09\uff0c\u672a\u53d1\u751f\u514d\u75ab\u6548\u5e94\u7ec6\u80de\u76f8\u5173\u795e\u7ecf\u6bd2\u6027\u7efc\u5408\u5f81\uff08Immune effector Cell-Associated Neurotoxicity Syndrome\uff0cICANS\uff09\uff0c\u22653\u7ea7\u7684\u8840\u7ec6\u80de\u51cf\u5c11\u5747\u5728\u56de\u8f93\u540e4\u5468\u5185\u6062\u590d\u3002\u76f8\u8f83\u4e8e\u5728\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u9002\u5e94\u75c7\u7814\u7a76\u4e2d\u7684\u5b89\u5168\u6027\u8c31\uff0c\u672a\u53d1\u73b0\u65b0\u7684\u5b89\u5168\u6027\u98ce\u9669\uff0c\u4e14\u5b89\u5168\u6027\u66f4\u4f18\u3002 \u6709\u6548\u6027\uff1a2\u4f8b\u53d7\u8bd5\u8005\u7684\u4e34\u5e8a\u75c7\u72b6\u6301\u7eed\u6539\u5584\u8d85\u8fc718\u4e2a\u6708\u3002\u4f0a\u57fa\u5965\u4ed1\u8d5b\u6ce8\u5c04\u6db2\u56de\u8f93\u540e3\u4e2a\u6708\u5f00\u59cb\uff0c\u60a3\u8005\u80a2\u529b\u548c\u80ba\u6d3b\u91cf\u660e\u663e\u6539\u5584\uff0c\u91cd\u75c7\u808c\u65e0\u529b-\u65e5\u5e38\u751f\u6d3b\u6d3b\u52a8\u8bc4\u5206\uff08MG-ADL\uff09\u3001\u91cd\u75c7\u808c\u65e0\u529b\u5b9a\u91cf\u8bc4\u5206\uff08QMG\uff09\u3001\u91cd\u75c7\u808c\u65e0\u529b-\u751f\u6d3b\u8d28\u91cf\u8bc4\u5206\uff08MG-QOL\uff09\u548c\u6539\u826fRankin\u8bc4\u5206\uff08mRS\uff09\u6301\u7eed\u6539\u5584\u3002\u968f\u8bbf\u671f\u95f4\u9664\u5916\u4f4e\u5242\u91cf\u65b0\u65af\u7684\u660e\uff08\u5206\u522b\u4e3a90mg\/\u5929\u548c60mg\/\u5929\uff09\uff0c\u672a\u5408\u5e76\u4f7f\u7528\u5176\u4ed6\u514d\u75ab\u8c03\u8282\u6cbb\u7597\u3002 PK\/PD\uff1a\u4f0a\u57fa\u5965\u4ed1\u8d5b\u6ce8\u5c04\u6db2\u56de\u8f93\u540e\u5728\u53d7\u8bd5\u8005\u4f53\u5185\u6269\u589e\u826f\u597d\uff0c\u6301\u7eed\u65f6\u95f4\u8f83\u77ed\u30022\u4f8b\u53d7\u8bd5\u8005\u7684\u6297AChR\u548c\u6297Titin\u6297\u4f53\u3001\u6297MuSK\u6297\u4f53\u5728\u56de\u8f93\u540e\u5747\u8fc5\u901f\u964d\u4f4e\u5e76\u957f\u671f\u7ef4\u6301\u5728\u6781\u4f4e\u6c34\u5e73\u30022\u4f8b\u53d7\u8bd5\u8005\u7684B\u7ec6\u80de\u548c\u6d46\u7ec6\u80de\u5728\u56de\u8f93\u540e2\u4e2a\u6708\u5185\u964d\u4f4e\u81f3\u65e0\u6cd5\u68c0\u6d4b\uff0c\u800c\u540e\u9010\u6e10\u6062\u590d\u3002\u4e24\u4f8b\u53d7\u8bd5\u8005\u7684B\u7ec6\u80de\u5728\u56de\u8f93\u540e18\u4e2a\u6708\u5747\u5df2\u6062\u590d\u81f3\u6b63\u5e38\u6c34\u5e73\uff0c\u5176\u4e2d\u7ea680%\u4e3a\u5e7c\u7a1aB\u7ec6\u80de\uff0c\u800c\u6d46\u7ec6\u80de\u4ecd\u7ef4\u6301\u8f83\u4f4e\u6c34\u5e73\u3002\u8be5\u7ed3\u679c\u663e\u793aCAR-T\u7ec6\u80de\u6cbb\u7597\u7684\u957f\u671f\u7597\u6548\uff0c\u53ef\u80fd\u4e0e\u5e7c\u7a1a\u8868\u578b\u4e3a\u4e3b\u7684B\u7ec6\u80de\u91cd\u5efa\u800c\u6d46\u7ec6\u80de\u6301\u7eed\u6e05\u9664\u6709\u5173\u3002 \u6b64\u9879\u7814\u7a76\u4e3b\u8981\u7814\u7a76\u8005\uff0c\u534e\u4e2d\u79d1\u6280\u5927\u5b66\u540c\u6d4e\u533b\u5b66\u9662\u9644\u5c5e\u540c\u6d4e\u533b\u9662\u738b\u4f1f\u6559\u6388\u8868\u793a\uff1a&quot;\u91cd\u75c7\u808c\u65e0\u529b\u75c5\u7a0b\u957f\u3001\u96be\u6cbb\u6108\u3001\u6613\u590d\u53d1\uff0c\u5f53\u524d\u4f20\u7edf\u836f\u7269\u7684\u6cbb\u7597\u867d\u5728\u4e00\u5b9a\u7a0b\u5ea6\u4e0a\u80fd\u6539\u5584\u808c\u65e0\u529b\u75c7\u72b6\uff0c\u4f46\u5728\u75be\u75c5\u63a7\u5236\u3001\u957f\u671f\u5b89\u5168\u6027\u7b49\u65b9\u9762\u5747\u5b58\u5728\u4e0d\u8db3\uff0c\u60a3\u8005\u5bf9\u66f4\u597d\u7684\u4e34\u5e8a\u7ed3\u5c40\u548c\u6cbb\u7597\u65b9\u5f0f\u6709\u8feb\u5207\u9700\u6c42\u3002\u5728\u6211\u4eec\u6b64\u6b21\u7684IIT\u7814\u7a76\u4e2d\uff0c\u5f88\u9ad8\u5174\u5730\u770b\u5230BCMA CAR-T\u7ec6\u80de\u7597\u6cd5\u53ef\u4ee5\u963b\u6b62MG\u75be\u75c5\u8fdb\u5c55\uff0c\u5e76\u8868\u73b0\u51fa\u9006\u8f6c\u75be\u75c5\u5f81\u8c61\uff0c\u6709\u671b\u6539\u53d8MG\u6cbb\u7597\u683c\u5c40\uff0c\u4e3a\u60a3\u8005\u5e26\u6765\u6cbb\u6108\u7684\u5e0c\u671b\u3002&quot; \u9664\u672c\u6b21\u53d1\u8868\u7684\u7814\u7a76\u7ed3\u679c\u5916\uff0c\u9a6f\u9e7f\u751f\u7269\u548c\u7814\u7a76\u8005\u56e2\u961f\u4ecd\u5728\u6301\u7eed\u63a2\u7d22\u4f0a\u57fa\u5965\u4ed1\u8d5b\u6ce8\u5c04\u6db2\u5728\u6cbb\u7597\u5176\u4ed6\u6297\u4f53\u4ecb\u5bfc\u7684\u81ea\u8eab\u514d\u75ab\u6027\u75be\u75c5\u5305\u62ec\u89c6\u795e\u7ecf\u810a\u9ad3\u708e\u8c31\u7cfb\u75be\u75c5\uff08NMOSD\uff09\u3001\u514d\u75ab\u4ecb\u5bfc\u6027\u574f\u6b7b\u6027\u808c\u75c5\uff08IMNM\uff09\u4ee5\u53ca\u6162\u6027\u708e\u6027\u8131\u9ad3\u9798\u6027\u591a\u53d1\u6027\u795e\u7ecf\u75c5\uff08CIDP\uff09\u4e2d\u7684\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\uff0c\u81f4\u529b\u4e8e\u6539\u53d8\u81ea\u514d\u75be\u75c5\u7684\u6cbb\u7597\u683c\u5c40\u3002&hellip; <a class=\"read-more\" href=\"https:\/\/www.xinwengao.com\/cn\/pr\/20240228192200106367\">Read More<\/a><\/p>\n","protected":false},"author":556,"featured_media":106370,"comment_status":"close","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1965],"tags":[],"class_list":["post-106367","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-partnerships"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/106367","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/users\/556"}],"replies":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/comments?post=106367"}],"version-history":[{"count":1,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/106367\/revisions"}],"predecessor-version":[{"id":106369,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/106367\/revisions\/106369"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media\/106370"}],"wp:attachment":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media?parent=106367"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/categories?post=106367"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/tags?post=106367"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}